Request Form
To see if you are eligible to participate in this program, please CLICK HERE
Learning Materials – One-Pagers
AIM-LO (ASCVD Identification and Management of Lipid Lowering Therapy) is a Canadian initiative to educate, encourage and motivate community-based specialists to ensure patients with dyslipidemia who are at high risk of cardiovascular events are optimized on lipid-lowering therapy as recommended by the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines.
View and download the one-pagers below to learn about the guidelines, LDL-cholesterol, therapeutic management of ASCVD, and more.
Overview of 2021 CCS Dyslipidemia Guidelines: Focus on Secondary Prevention
Insights into the updated recommendations for managing dyslipidemia in adults with ASCVD, highlighting patients defined as high-risk of cardiovascular events.
Download
LDL-C: Lower for Longer is Better
Read about the connection between elevated LDL and atherosclerosis and how the concept of 'cholesterol-years' explains how cumulative lifetime exposure to LDL-cholesterol affects cardiovascular risk.
Download
Non-HDL Cholesterol: Evolving Evidence Leads to a Novel Strategy
An explanation of why non-HDL cholesterol is now defined as the preferred measurement over LDL-C, particularly for patients with elevated triglycerides, in the 2021 CCS Dyslipidemia guidelines.
Download
Key Tips to Maximize Therapeutic Access for Your Patients
Best practices and valuable strategies for utilizing your electronic health record system (EHR) as a tool to maximize therapeutic access for your patients.
Download
Statins + Ezetimibe
The benefits of combining statins and ezetimibe in secondary prevention and the challenges patients face in lowering LDL-C aggressively with statin therapy alone.
Download
Icosapent ethyl (IPE)
The role of IPE, a non-statin therapy containing highly purified omega-3 fatty acid EPA, for the reduction of triglycerides in patients with ASCVD and the updated recommendation in the Canadian Cardiovascular Society's guidelines.
Download
PCSK9 Inhibition (mAbs and siRNA)
Read about the role of PCSK9 in ASCVD and the two approaches to PCSK9 inhibition: monoclonal antibodies (mAbs) and small interfering RNA (siRNA). Answers to FAQs, mechanisms of action, dosing regimens, efficacy and safety profiles of evolocumab, alirocumab, and inclisiran, and insights from more recent clinical trials.
Download